Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Dean Liu -- 2060 2022-11-14 01:31:37

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Abiraterone. Encyclopedia. Available online: https://encyclopedia.pub/entry/34436 (accessed on 24 September 2026).
HandWiki. Abiraterone. Encyclopedia. Available at: https://encyclopedia.pub/entry/34436. Accessed September 24, 2026.
HandWiki. "Abiraterone" Encyclopedia, https://encyclopedia.pub/entry/34436 (accessed September 24, 2026).
HandWiki. (2022, November 14). Abiraterone. In Encyclopedia. https://encyclopedia.pub/entry/34436
HandWiki. "Abiraterone." Encyclopedia. Web. 14 November, 2022.
Abiraterone
Edit
The content is sourced from: https://handwiki.org/wiki/Chemistry:Abiraterone

Abiraterone, also known as abiraterone acetate and sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It should either be used following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is taken by mouth. Common side effects include tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include liver failure and adrenocortical insufficiency. In males who partners can become pregnant, birth control is recommended. Supplied as abiraterone acetate it is converted in the body to abiraterone. Abiraterone works by suppressing the production of androgens – specifically it inhibits CYP17A1 – and thereby decreases the production of testosterone. In doing so, it prevents the effects of these hormones in prostate cancer. Abiraterone was described in 1995, and approved for medical use in the United States and Europe in 2011. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. In the United Kingdom it costs the NHS £2,735 a month as of 2018. In the United States this amount costs US$3,276 as of 2019. The medication is marketed widely throughout the world.

abiraterone acetate health medical use

References

  1. "ZYTIGA- abiraterone acetate tablet, film coated". 13 June 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513. 
  2. "Zytiga EPAR". European Medicines Agency. 13 March 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga. 
  3. "ZYTIGA 500 mg film-coated tablets - Summary of Product Characteristics (SmPC)". electronic medicines compendium (emc). Datapharm. 4 March 2019. https://www.medicines.org.uk/emc/product/2381/smpc. 
  4. "Zytiga abiraterone acetate product information" (PDF). TGA eBusiness Services. Janssen-Cilag Pty Ltd. 1 March 2012. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01395-3. 
  5. "Pharmaceutical Benefits Scheme - Abiraterone". Pharmaceutical Benefits Scheme. http://www.pbs.gov.au/medicine/item/2698B. 
  6. "Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms". J Natl Compr Canc Netw 13 (7): e49–55. July 2015. doi:10.6004/jnccn.2015.0109. PMID 26150586.  https://dx.doi.org/10.6004%2Fjnccn.2015.0109
  7. "Abiraterone and increased survival in metastatic prostate cancer". The New England Journal of Medicine 364 (21): 1995–2005. May 2011. doi:10.1056/NEJMoa1014618. PMID 21612468.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3471149
  8. "Abiraterone in metastatic prostate cancer without previous chemotherapy". The New England Journal of Medicine 368 (2): 138–48. January 2013. doi:10.1056/NEJMoa1209096. PMID 23228172.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3683570
  9. "Zytiga prescribing information". Janssen Biotech. May 2012. http://www.zytigahcp.com/pdf/full_prescribing_info.pdf. 
  10. "Zytiga (abiraterone) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. http://reference.medscape.com/drug/zytiga-abiraterone-999651. 
  11. "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture". Journal of Steroid Biochemistry 31 (5): 845–52. November 1988. doi:10.1016/0022-4731(88)90295-6. PMID 2462135.  https://dx.doi.org/10.1016%2F0022-4731%2888%2990295-6
  12. "Abiraterone and spironolactone in prostate cancer: a combination to avoid". Acta Clinica Belgica: 1–6. November 2018. doi:10.1080/17843286.2018.1543827. PMID 30477405.  https://dx.doi.org/10.1080%2F17843286.2018.1543827
  13. Neidle, Stephen (30 September 2013). Cancer Drug Design and Discovery. Academic Press. pp. 341–342. ISBN 978-0-12-397228-6. https://books.google.com/books?id=HS6IAAAAQBAJ&pg=PA342. 
  14. "Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency". Pharmaceuticals 11 (2): 37. April 2018. doi:10.3390/ph11020037. PMID 29710837.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6027421
  15. "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer". BJU International 96 (9): 1241–6. December 2005. doi:10.1111/j.1464-410X.2005.05821.x. PMID 16287438.  https://dx.doi.org/10.1111%2Fj.1464-410X.2005.05821.x
  16. "Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die?". Journal of Clinical Oncology 32 (33): 3689–91. November 2014. doi:10.1200/JCO.2014.57.8534. PMID 25311216. "Abiraterone acetate is a prodrug for abiraterone, a CYP17 inhibitor, which has the capacity to lower serum testosterone levels to less than 1 ng/dL (compared with levels closer to 20 ng/dL that are achieved with conventional ADT).19 [...] Relative to LHRHa alone, the addition of abiraterone resulted in an 85% decline in dihydrotestosterone (DHT) levels, a 97% to 98% decline in dehydroepiandrosterone (DHEA) levels, and a 77% to 78% decline in androstenedione levels.".  https://dx.doi.org/10.1200%2FJCO.2014.57.8534
  17. Tindall, Donald J.; James, Mohler (20 April 2009). Androgen Action in Prostate Cancer. Springer Science & Business Media. pp. 748–. ISBN 978-0-387-69179-4. https://books.google.com/books?id=L6NMZizNLMoC&pg=PA748. 
  18. "CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents". Nature Reviews. Urology 11 (1): 32–42. January 2014. doi:10.1038/nrurol.2013.274. PMID 24276076.  https://dx.doi.org/10.1038%2Fnrurol.2013.274
  19. "CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2". The Journal of Steroid Biochemistry and Molecular Biology 174: 192–200. November 2017. doi:10.1016/j.jsbmb.2017.09.007. PMID 28893623.  https://dx.doi.org/10.1016%2Fj.jsbmb.2017.09.007
  20. "Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis". Biochemical and Biophysical Research Communications 477 (4): 1005–1010. September 2016. doi:10.1016/j.bbrc.2016.07.019. PMID 27395338.  https://dx.doi.org/10.1016%2Fj.bbrc.2016.07.019
  21. "Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer". Nature 523 (7560): 347–51. July 2015. doi:10.1038/nature14406. PMID 26030522.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4506215
  22. "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy". Nature 533 (7604): 547–51. May 2016. doi:10.1038/nature17954. PMID 27225130. PMC 5111629. https://dash.harvard.edu/bitstream/handle/1/29626087/5111629.pdf?sequence=1. 
  23. "The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer". Breast Cancer Research and Treatment 157 (1): 23–30. May 2016. doi:10.1007/s10549-016-3774-3. PMID 27083183.  https://dx.doi.org/10.1007%2Fs10549-016-3774-3
  24. "Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules". Oncology 84 (2): 92–9. 2013. doi:10.1159/000343821. PMID 23128186.  https://dx.doi.org/10.1159%2F000343821
  25. Figg, William D.; Chau, Cindy H.; Small, Eric J. (14 September 2010). Drug Management of Prostate Cancer. Springer Science & Business Media. p. 97. ISBN 978-1-60327-829-4. https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA97. 
  26. Rosenthal, Laura; Burchum, Jacqueline (17 February 2017). Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book. Elsevier Health Sciences. pp. 936. ISBN 978-0-323-44779-9. https://books.google.com/books?id=gfYoDgAAQBAJ&pg=PA936. 
  27. "Identification of Galeterone and Abiraterone as Inhibitors of Dehydroepiandrosterone Sulfonation Catalyzed by Human Hepatic Cytosol, SULT2A1, SULT2B1b, and SULT1E1". Drug Metabolism and Disposition 46 (4): 470–482. April 2018. doi:10.1124/dmd.117.078980. PMID 29436390.  https://dx.doi.org/10.1124%2Fdmd.117.078980
  28. "Where did abiraterone come from?". Cancer Research UK. 2011-09-21. http://scienceblog.cancerresearchuk.org/2011/09/21/where-did-abiraterone-come-from/. 
  29. "A new way to treat prostate cancer: The story of abiraterone". The Institute of Cancer Research. 2012-09-10. http://www.icr.ac.uk/press/recent_featured_articles/Story_Abiraterone/index.shtml. 
  30. "Abiraterone Acetate (CB7630)". Cougar Biotechnology. Archived from the original. Error: If you specify |archiveurl=, you must also specify |archivedate=. https://web.archive.org/web/20080907194739/http://www.cougarbiotechnology.com/cb7630.html. 
  31. "Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc" (Press release). Cougar Biotechnology. 2009-05-11. Archived from the original on 2009-05-29. Retrieved 2009-06-03. https://web.archive.org/web/20090529115329/http://www.cougarbiotechnology.com/pr052109.html
  32. "Drugs@FDA - FDA Approved Drug Products - Zytiga". https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202379. 
  33. "FDA approves Zytiga for late-stage prostate cancer" (Press release). Food and Drug Administration (FDA). 2011-04-28. Archived from the original on 2017-01-12. https://wayback.archive-it.org/7993/20170112024032/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.htm
  34. "FDA Approval for Abiraterone Acetate". U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/fda-abirateroneacetate. 
  35. "EMA assessment of Zytiga (abiraterone)". European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002321/human_med_001499.jsp&mid=WC0b01ac058001d124. 
  36. "Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination guidance". NICE guidance. 15 May 2012. http://www.nice.org.uk/nicemedia/live/13484/59217/59217.pdf. 
  37. "NICE technology appraisal guidance [TA259]". NICE guidance. June 2012. http://www.nice.org.uk/guidance/ta259/chapter/1-guidance. 
  38. "NICE appraisal of earlier treatment with abiraterone for prostate cancer". NICE press release. 14 August 2014. http://www.nice.org.uk/nice-appraisal-of-earlier-treatment-with-abiraterone-for-prostate-cancer. 
  39. NCI Staff. "Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer". National Cancer Institute (NCI). https://www.cancer.gov/news-events/cancer-currents-blog/2018/abiraterone-fda-prostate-hormone-sensitive. 
  40. "Abiraterone". Drugs.com. https://www.drugs.com/international/abiraterone.html. 
  41. "abiraterone". https://mednet-communities.net/inn/db/ViewINN.aspx?i=7375. 
  42. "Abiraterone acetate - Johnson & Johnson". Adis Insight. http://adisinsight.springer.com/drugs/800005133. 
  43. "Generic Zytiga Availability". Drugs.com. https://www.drugs.com/availability/generic-zytiga.html. 
  44. "Generic Yonsa Availability". Drugs.com. https://www.drugs.com/availability/generic-yonsa.html. 
  45. "BTG International Limited v. Amneal Pharmaceuticals LLC". United States Court of Appeals for the Federal Circuit. 2019-05-14. http://www.cafc.uscourts.gov/node/24791. 
  46. "Sun Pharma Gets FDA Go-Ahead for Yonsa for Prostate Cancer". https://www.biospace.com/article/sun-pharma-gets-fda-go-ahead-for-yonsa-for-prostate-cancer/. 
  47. "Sun Pharma Announces USFDA Approval of YONSA (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone" (Press release). Sun Pharmaceutical Industries Limited/Churchill Pharmaceuticals. 23 May 2018. Archived from the original on 15 November 2019. Retrieved 14 November 2019 – via Business Wire. https://www.businesswire.com/news/home/20180522006497/en/Sun-Pharma-Announces-USFDA-Approval-YONSA%C2%AE-abiraterone
  48. "YONSA- abiraterone acetate tablet". 5 June 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8967e10-f768-47ce-ac9e-2324c8390132. 
  49. British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 921. ISBN 9780857113382. 
  50. "Abiraterone Prices, Coupons & Patient Assistance Programs" (in en). https://www.drugs.com/price-guide/abiraterone. 
  51. "PROPOSAL FOR THE INCLUSION OF ENZALUTAMIDE AND ABIRATERONE ACETATE IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES FOR THE TREATMENT OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER". p. 22, 25. https://www.who.int/selection_medicines/committees/expert/22/applications/8.3_enzalutamide-abiraterone.pdf. Retrieved 26 November 2019. 
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 3.0K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 14 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback